The valsartan class action lawsuit has alleged that the recalled generic versions of the blood pressure medication distributed in recent years should be considered as an unapproved drug due to the presence of carcinogenic impurities.
According to a complaint filed last week in the U.S. District Court for the District of New Jersey, the plaintiff has alleged that the valsartan manufacturers illegally sold contaminated drugs and falsely advertised them as generic valsartan equivalents, cheating hundreds of thousands of consumers and putting their health at risk. The allegations were on behalf of all Florida residents who purchased recalled generic valsartan products manufactured and distributed by Zhejiang Huahai Pharmaceutical Co., Ltd., Solco Healthcare U.S., and Prinston Pharmaceutical, Inc., who are all defendants in the claim.
There are currently 10 class action lawsuits and one individual action pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.
